Which has higher earnings and valuation, ZTS or GSK?

GSK has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zoetis $9.47B 3.05 $2.67B $6.07 11.50 GSK $43.07B 2.21 $7.54B $3.20 14.69

Is ZTS or GSK more profitable?

Zoetis has a net margin of 27.49% compared to GSK's net margin of 14.56%. Zoetis' return on equity of 74.89% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets Zoetis 27.49% 74.89% 18.59% GSK 14.56% 43.23% 11.60%

Does the media refer more to ZTS or GSK?

In the previous week, Zoetis had 4 more articles in the media than GSK. MarketBeat recorded 8 mentions for Zoetis and 4 mentions for GSK. Zoetis' average media sentiment score of 0.43 beat GSK's score of 0.00 indicating that Zoetis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral GSK 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, ZTS or SNY?

Sanofi has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zoetis $9.47B 3.05 $2.67B $6.07 11.50 Sanofi $49.35B 1.95 $8.84B $1.91 20.82

Is ZTS or SNY more profitable?

Zoetis has a net margin of 27.49% compared to Sanofi's net margin of 8.66%. Zoetis' return on equity of 74.89% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Zoetis 27.49% 74.89% 18.59% Sanofi 8.66% 14.19% 7.95%

Does the media refer more to ZTS or SNY?

In the previous week, Sanofi had 2 more articles in the media than Zoetis. MarketBeat recorded 10 mentions for Sanofi and 8 mentions for Zoetis. Sanofi's average media sentiment score of 0.61 beat Zoetis' score of 0.43 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Sanofi 2 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TAK or ZTS?

Zoetis has a consensus price target of $101.08, suggesting a potential upside of 44.80%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Zoetis 2 Sell rating(s) 9 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.32

Does the media prefer TAK or ZTS?

In the previous week, Takeda Pharmaceutical had 4 more articles in the media than Zoetis. MarketBeat recorded 12 mentions for Takeda Pharmaceutical and 8 mentions for Zoetis. Zoetis' average media sentiment score of 0.43 beat Takeda Pharmaceutical's score of 0.24 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Zoetis 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media favor ZTS or TEVA?

In the previous week, Teva Pharmaceutical Industries had 16 more articles in the media than Zoetis. MarketBeat recorded 24 mentions for Teva Pharmaceutical Industries and 8 mentions for Zoetis. Teva Pharmaceutical Industries' average media sentiment score of 0.59 beat Zoetis' score of 0.43 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Teva Pharmaceutical Industries 7 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ONC or ZTS?

Zoetis has higher revenue and earnings than BeOne Medicines. Zoetis is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.34B 7.25 $286.93M $5.68 62.09 Zoetis $9.47B 3.05 $2.67B $6.07 11.50

Is ONC or ZTS more profitable?

Zoetis has a net margin of 27.49% compared to BeOne Medicines' net margin of 10.70%. Zoetis' return on equity of 74.89% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 10.70% 14.23% 7.82% Zoetis 27.49% 74.89% 18.59%

Does the media prefer ONC or ZTS?

In the previous week, BeOne Medicines had 3 more articles in the media than Zoetis. MarketBeat recorded 11 mentions for BeOne Medicines and 8 mentions for Zoetis. BeOne Medicines' average media sentiment score of 0.57 beat Zoetis' score of 0.43 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zoetis 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Zoetis (ZTS) Competitors

$69.68 +0.58 (+0.84%)

As of 02:10 PM Eastern

Compare

ZTS vs. GSK, SNY, TAK, TEVA, and ONC

Should you buy Zoetis stock or one of its competitors? Zoetis's main competitors and comparable companies include GSK (GSK), Sanofi (SNY), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), and BeOne Medicines (ONC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Zoetis compare to GSK?

Zoetis (NYSE:ZTS) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Zoetis presently has a consensus price target of $101.08, indicating a potential upside of 44.80%. GSK has a consensus price target of $56.50, indicating a potential upside of 20.17%. Given Zoetis' stronger consensus rating and higher probable upside, equities analysts clearly believe Zoetis is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
GSK	2 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.09

GSK has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.05	$2.67B	$6.07	11.50
GSK	$43.07B	2.21	$7.54B	$3.20	14.69

In the previous week, Zoetis had 4 more articles in the media than GSK. MarketBeat recorded 8 mentions for Zoetis and 4 mentions for GSK. Zoetis' average media sentiment score of 0.43 beat GSK's score of 0.00 indicating that Zoetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
GSK	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zoetis has a net margin of 27.49% compared to GSK's net margin of 14.56%. Zoetis' return on equity of 74.89% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.49%	74.89%	18.59%
GSK	14.56%	43.23%	11.60%

Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 3.0%. GSK pays an annual dividend of $1.78 per share and has a dividend yield of 3.8%. Zoetis pays out 34.9% of its earnings in the form of a dividend. GSK pays out 55.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 14 consecutive years.

Zoetis has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, GSK has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Zoetis beats GSK on 14 of the 20 factors compared between the two stocks.

How does Zoetis compare to Sanofi?

Zoetis (NYSE:ZTS) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Zoetis has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market.

Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 3.0%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.4%. Zoetis pays out 34.9% of its earnings in the form of a dividend. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zoetis has raised its dividend for 14 consecutive years.

Sanofi has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.05	$2.67B	$6.07	11.50
Sanofi	$49.35B	1.95	$8.84B	$1.91	20.82

In the previous week, Sanofi had 2 more articles in the media than Zoetis. MarketBeat recorded 10 mentions for Sanofi and 8 mentions for Zoetis. Sanofi's average media sentiment score of 0.61 beat Zoetis' score of 0.43 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Sanofi	2 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Zoetis has a net margin of 27.49% compared to Sanofi's net margin of 8.66%. Zoetis' return on equity of 74.89% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.49%	74.89%	18.59%
Sanofi	8.66%	14.19%	7.95%

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Zoetis currently has a consensus target price of $101.08, indicating a potential upside of 44.80%. Sanofi has a consensus target price of $49.50, indicating a potential upside of 24.48%. Given Zoetis' higher probable upside, research analysts clearly believe Zoetis is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
Sanofi	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.38

Summary

Zoetis beats Sanofi on 11 of the 20 factors compared between the two stocks.

How does Zoetis compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

In the previous week, Takeda Pharmaceutical had 4 more articles in the media than Zoetis. MarketBeat recorded 12 mentions for Takeda Pharmaceutical and 8 mentions for Zoetis. Zoetis' average media sentiment score of 0.43 beat Takeda Pharmaceutical's score of 0.24 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zoetis	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 3.0%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zoetis pays out 34.9% of its earnings in the form of a dividend. Zoetis has increased its dividend for 14 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Zoetis has a net margin of 27.49% compared to Takeda Pharmaceutical's net margin of 3.80%. Zoetis' return on equity of 74.89% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Zoetis	27.49%	74.89%	18.59%

Zoetis has a consensus price target of $101.08, suggesting a potential upside of 44.80%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

Takeda Pharmaceutical has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Zoetis has lower revenue, but higher earnings than Takeda Pharmaceutical. Zoetis is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	2.02	-$1.01B	$0.34	52.40
Zoetis	$9.47B	3.05	$2.67B	$6.07	11.50

Summary

Zoetis beats Takeda Pharmaceutical on 15 of the 20 factors compared between the two stocks.

How does Zoetis compare to Teva Pharmaceutical Industries?

Zoetis (NYSE:ZTS) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Teva Pharmaceutical Industries had 16 more articles in the media than Zoetis. MarketBeat recorded 24 mentions for Teva Pharmaceutical Industries and 8 mentions for Zoetis. Teva Pharmaceutical Industries' average media sentiment score of 0.59 beat Zoetis' score of 0.43 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	7 Very Positive mention(s)	5 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zoetis has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Zoetis is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.05	$2.67B	$6.07	11.50
Teva Pharmaceutical Industries	$17.26B	2.65	$1.41B	$0.60	65.45

Zoetis has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Zoetis has a net margin of 27.49% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Zoetis' return on equity of 74.89% beat Teva Pharmaceutical Industries' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.49%	74.89%	18.59%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

Zoetis presently has a consensus price target of $101.08, indicating a potential upside of 44.80%. Teva Pharmaceutical Industries has a consensus price target of $44.67, indicating a potential upside of 13.74%. Given Zoetis' higher possible upside, equities analysts clearly believe Zoetis is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.92

92.8% of Zoetis shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Zoetis and Teva Pharmaceutical Industries tied by winning 8 of the 16 factors compared between the two stocks.

How does Zoetis compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, BeOne Medicines had 3 more articles in the media than Zoetis. MarketBeat recorded 11 mentions for BeOne Medicines and 8 mentions for Zoetis. BeOne Medicines' average media sentiment score of 0.57 beat Zoetis' score of 0.43 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Zoetis has higher revenue and earnings than BeOne Medicines. Zoetis is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.25	$286.93M	$5.68	62.09
Zoetis	$9.47B	3.05	$2.67B	$6.07	11.50

BeOne Medicines presently has a consensus target price of $404.14, indicating a potential upside of 14.60%. Zoetis has a consensus target price of $101.08, indicating a potential upside of 44.80%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.06
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

BeOne Medicines has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

Zoetis has a net margin of 27.49% compared to BeOne Medicines' net margin of 10.70%. Zoetis' return on equity of 74.89% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Zoetis	27.49%	74.89%	18.59%

Summary

Zoetis beats BeOne Medicines on 9 of the 17 factors compared between the two stocks.

Get Zoetis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZTS vs. The Competition

Export

Metric	Zoetis	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$28.92B	$12.21B	$7.11B	$22.67B
Dividend Yield	3.04%	2.63%	2.53%	3.74%
P/E Ratio	11.53	799.68	274.41	27.77
Price / Sales	3.05	751.97	608.04	20.15
Price / Cash	9.23	81.79	77.38	39.56
Price / Book	9.23	10.39	10.90	4.64
Net Income	$2.67B	$2.84B	$3.50B	$1.08B
7 Day Performance	-1.66%	-1.77%	-2.15%	-1.06%
1 Month Performance	-8.42%	-6.05%	-6.41%	-5.03%
1 Year Performance	-52.34%	-3.67%	8.88%	5.75%

Zoetis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZTS Zoetis	4.8411 of 5 stars	$69.85 +1.1%	$101.08 +44.7%	-53.0%	$28.88B	$9.47B	11.52	14,500
GSK GSK	3.8889 of 5 stars	$49.68 +0.9%	$56.50 +13.7%	+3.6%	$100.49B	$43.07B	15.54	66,841	Dividend Cut
SNY Sanofi	4.1872 of 5 stars	$41.18 +0.2%	$49.50 +20.2%	-18.3%	$99.84B	$49.35B	21.56	76,493	Trending News Gap Down
TAK Takeda Pharmaceutical	1.6631 of 5 stars	$18.90 +0.2%	N/A	+21.1%	$60.54B	$28.32B	55.57	47,000	News Coverage
TEVA Teva Pharmaceutical Industries	3.6782 of 5 stars	$38.84 -0.9%	$43.73 +12.6%	+96.4%	$45.26B	$17.26B	64.73	33,950	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ZTS) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zoetis (ZTS) Competitors

ZTS vs. GSK, SNY, TAK, TEVA, and ONC

How does Zoetis compare to GSK?

Summary

How does Zoetis compare to Sanofi?

Summary

How does Zoetis compare to Takeda Pharmaceutical?

Summary

How does Zoetis compare to Teva Pharmaceutical Industries?

Summary

How does Zoetis compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS vs. The Competition

Zoetis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zoetis (ZTS) Competitors

ZTS vs. GSK, SNY, TAK, TEVA, and ONC

How does Zoetis compare to GSK?

Do analysts recommend ZTS or GSK?

Which has higher earnings and valuation, ZTS or GSK?

Does the media refer more to ZTS or GSK?

Is ZTS or GSK more profitable?

Is ZTS or GSK a better dividend stock?

Which has more risk and volatility, ZTS or GSK?

Do insiders and institutionals hold more shares of ZTS or GSK?

Summary

How does Zoetis compare to Sanofi?

Which has more volatility and risk, ZTS or SNY?

Is ZTS or SNY a better dividend stock?

Which has better earnings and valuation, ZTS or SNY?

Does the media refer more to ZTS or SNY?

Is ZTS or SNY more profitable?

Do insiders and institutionals hold more shares of ZTS or SNY?

Do analysts rate ZTS or SNY?

Summary

How does Zoetis compare to Takeda Pharmaceutical?

Does the media prefer TAK or ZTS?

Is TAK or ZTS a better dividend stock?

Is TAK or ZTS more profitable?

Do analysts rate TAK or ZTS?

Which has more risk & volatility, TAK or ZTS?

Do institutionals and insiders hold more shares of TAK or ZTS?

Which has better valuation and earnings, TAK or ZTS?

Summary

How does Zoetis compare to Teva Pharmaceutical Industries?

Does the media favor ZTS or TEVA?

Which has preferable valuation and earnings, ZTS or TEVA?

Which has more risk & volatility, ZTS or TEVA?

Is ZTS or TEVA more profitable?

Do analysts rate ZTS or TEVA?

Do insiders and institutionals believe in ZTS or TEVA?

Summary

How does Zoetis compare to BeOne Medicines?

Do insiders & institutionals hold more shares of ONC or ZTS?

Does the media prefer ONC or ZTS?

Which has higher valuation and earnings, ONC or ZTS?

Do analysts rate ONC or ZTS?

Which has more risk and volatility, ONC or ZTS?

Is ONC or ZTS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS vs. The Competition

Zoetis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools